Clin Psychopharmacol Neurosci.
2021 Feb;19(1):160-165. 10.9758/cpn.2021.19.1.160.
A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat
- Affiliations
-
- 1Departments of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Departments of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 3Department of Biomedical and Neuromotor Sciences, Psychiatric Section, University of Bologna, Bologna, Italy
- 4Cell Death Disease Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
- KMID: 2513402
- DOI: http://doi.org/10.9758/cpn.2021.19.1.160
Abstract
Objective
We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment-resistant major depressive disorder (TRD) patients in real practice.
Methods
Nine patients were prescribed NeuropharmagenⓇ for selection of antidepressants for individual patient and their clinical outcomes were followed.
Results
After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients.
Conclusion
Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Effects of BDNF Polymorphisms on Antidepressant Action
- Selection of an Antidepressant Based on the Genotypes of Cytochrome P450 Enzymes Genes in a Patient with Major Depressive Disorder
- Treatment Strategies for Psychotic Depression
- Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report
- Adherence to Antidepressants in Korean Elderly Patients with Major Depressive Disorder
